The Politics of Cure
Why an mRNA cancer vaccine reveals the struggle over trust, life, and abandonment in America
James B. Greenberg
Sep 04, 2025
We’ve all seen the hucksters: the miracle cures that promise easy solutions doctors and Big Pharma supposedly don’t want you to know about. These pitches work because they feed on mistrust, on the suspicion that the medical establishment hides what it cannot profit from. Usually, they are pure fiction. But this time, something extraordinary is happening that is very real.
At the University of Florida, researchers have developed an experimental mRNA cancer vaccine that doesn’t chase one narrow tumor protein. Instead, it shocks the immune system into behaving as if it were fighting a viral infection. In animal studies, it has eliminated bone, brain, and skin cancers, awakened dormant T-cells, and shown even more dramatic effects when paired with checkpoint inhibitors. The vaccine doesn’t just treat; it may create lasting immune memory, keeping tumors from returning.
That breakthrough represents a third paradigm in cancer vaccines. Traditional approaches target common tumor antigens. Personalized vaccines tailor themselves to an individual’s genetic mutations. But this new method aims higher: it primes the immune system broadly, letting it find and attack the cancer on its own. If clinical trials replicate these results, we may be staring at a universal, off-the-shelf cancer vaccine—a radical alternative to chemotherapy, radiation, and surgery.
And that is precisely what makes it so disruptive. An effective vaccine would not only save lives but also threaten the financial foundations of the cancer-treatment establishment—hospitals, oncology practices, and pharmaceutical companies whose revenue depends on the prolonged and costly regimens of chemotherapy, radiation, and targeted drug protocols.
Cancer care today is structured not around cures, but around continuity—multi-month regimens, lifelong protocols, and revenue streams calibrated to chronicity. Entire oncology departments, hospital budgets, and pharmaceutical pipelines are built on this model. A one-shot vaccine—or even a short series of injections—would overturn that architecture. In this sense, the barrier is not only scientific uncertainty or political hostility but also the structural interests of an industry organized to profit from treatment, not cure.
Here’s where Robert F. Kennedy Jr.’s anti-vax ideology suddenly makes sense. Since becoming Secretary of Health and Human Services, he has not raced to advance mRNA research. Instead, he has canceled half a billion dollars in federal mRNA contracts, terminated twenty-two ongoing projects, and ordered the Biomedical Advanced Research and Development Authority to stop initiating new mRNA research. [1] While his rhetoric focuses on COVID and respiratory vaccines, these cuts are dismantling the very infrastructure needed to carry forward discoveries like the cancer vaccine.
Here’s where anthropology helps us see what’s happening. At stake is not only science, but trust itself. For decades, public faith in medical institutions has been chipped away by profiteering, inequities, and corporate capture. Conspiracy theories thrive because they grow in the cracks left by real failures. Kennedy has become an ideological entrepreneur of that mistrust, channeling it into policy that erodes not only confidence but capacity.
Truth, anthropology of knowledge reminds us, is not self-evident; it must be cultivated, defended, and institutionally supported. Peer review, research funding, regulatory oversight—all of these are part of the scaffolding that makes discovery possible. When that scaffolding is stripped away, knowledge itself withers. What remains is not an open marketplace of ideas but a politics of suspicion, where ideology trumps evidence and lives hang in the balance.
Political ecology helps us see that these decisions are deeply material. Cancer vaccines are not just molecules; they are pathways of survival. Who funds them, who distributes them, and who receives them becomes a question of power. When Kennedy pulls federal support, he is not only trimming a budget line. He is redrawing the boundary of who will have access to life-saving treatment in the future—and who will not.
This is what biopolitics means in practice: governance of life itself. A state can choose to nurture populations through investment in public health, or it can choose to let some lives fall away. Necropolitics sharpens the point: when governments deny or withdraw support from technologies that extend life, they are making a decision about who is consigned to death. That choice may not be stated openly, but its effects are written in the bodies of patients who go without.
Look at the geopolitical contrast. In Germany and the Netherlands, governments are expanding support for BioNTech and CureVac, betting heavily on mRNA oncology. If the University of Florida’s approach works, a Dutch cancer patient could one day access a vaccine their American counterpart cannot—not because the science failed, but because the politics chose failure. The U.S. risks ceding not only biomedical leadership but also the basic ability to protect its citizens.
This is not just an argument about medicine. It is about the cultural fabric that makes trust in science possible. When officials frame public health as tyranny and vaccines as poison, the result is not merely rhetorical. It becomes structural, baked into budgets, policies, and institutions.
The tragedy is that healthcare has been commodified, that access is unequal, and that patients are too often treated as revenue streams rather than human beings. But instead of addressing those grievances, anti-mRNA politics channels them into destruction, gutting the very technologies that might deliver more equitable and effective care. And behind that ideological front, the entrenched economics of cancer treatment—hospitals, clinics, and pharmaceutical companies with billions at stake—may find it easier to let such breakthroughs stall than to upend the system on which they depend.
That is why this moment matters. The promise of an mRNA cancer vaccine is not just biomedical, but civilizational. It tests whether societies can sustain the trust, infrastructure, and political will necessary to translate breakthrough science into shared survival.
We face a choice: invest in discovery and share its benefits, or retreat into suspicion and accept preventable deaths as normal. These are not technical choices. They are cultural ones—decisions about who belongs, who is protected, and whose lives we are willing to abandon.
Endnotes
[1] ABC, CBS, and FOX news all ran the story of RFK Jr.’s budget cuts for mRNA research on August 5th 2025.
Suggested Readings
Bright, Rick A. “mRNA: A Missile Defense System for Biology.” Foreign Affairs, September 2021.
Foucault, Michel. The History of Sexuality, Volume 1: An Introduction. Translated by Robert Hurley. New York: Pantheon, 1978.
Lakoff, Andrew. Unprepared: Global Health in a Time of Emergency. Berkeley: University of California Press, 2017.
Löwy, Ilana. Virus, Vaccinations, and Biopolitics: The Changing Politics of Global Health. London: Routledge, 2020.
Mbembe, Achille. Necropolitics. Translated by Steven Corcoran. Durham, NC: Duke University Press, 2019.
Murphy, Michelle. Sick Building Syndrome and the Problem of Uncertainty: Environmental Politics, Technoscience, and Women Workers. Durham, NC: Duke University Press, 2006.
Petryna, Adriana. When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton: Princeton University Press, 2009.
Rose, Nikolas. The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton: Princeton University Press, 2007.
